Puma Biotechnology, Puma Biotechnology, Inc is a development stage biopharmaceutical company dedicated to in-licensing and developing novel therapeutics for the treatment of cancer. Puma Biotechnology was founded by Alan H. Auerbach, who previously served as Founder, Chief Executive Officer and President of Cougar Biotechnology, Inc, a company dedicated to in-licensing and developing drugs for the treatment of cancer. Cougar was acquired by Johnson & Johnson in July 2009 for approximately $1 billion.